当前位置: X-MOL 学术Pharmacol. Therapeut. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The central serotonin2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research
Pharmacology & Therapeutics ( IF 12.0 ) Pub Date : 2017-07-27 , DOI: 10.1016/j.pharmthera.2017.07.014
Céline Devroye , Adeline Cathala , Pier Vincenzo Piazza , Umberto Spampinato

The serotonin2B receptor (5-HT2BR), which was first cloned and characterized in the rat stomach fundus, is the most recent addition to the 5-HT2R family. While its involvement in the regulation of gastrointestinal, vascular, pulmonary and cardiac physiology has been widely investigated, its functional role within the central nervous system (CNS) has received much less attention. Nevertheless, when considering the data available in the literature with regards to the regulatory control exerted by the central 5-HT2BR on dopamine (DA) and serotonin (5-HT) neuron activity, a very interesting picture emerges and highlights the key role of these receptors for future therapeutic strategies of DA-related neuropsychiatric disorders.

Thus, the present review, by compiling molecular, biochemical, electrophysiological and behavioral findings from the literature of the past twenty years, aims at providing a sound analysis of the current knowledge supporting the interest of the central 5-HT2BR for future therapeutic avenues. First, we recall the neuroanatomical and functional data supporting the therapeutic relevance of the 5-HT/DA interaction in the CNS. Thereafter, after a short overview of the central expression and molecular properties of the 5-HT2BR, as well as of the 5-HT2BR agonists and antagonists available in the market, we will focus on the functional role of this receptor in the control of 5-HT, DA and neuroglia activity in the rodent brain. Finally, the therapeutic potential of 5-HT2BR antagonists for improved treatment of schizophrenia and drug addiction will be discussed.



中文翻译:

中心血清素2B受体作为治疗多巴胺相关神经精神疾病的新药理靶点:理论基础和当前研究现状

血清素2B受体(5-HT 2B R)是5-HT 2 R家族的最新成员,它是首先在大鼠胃底克隆并鉴定的。尽管已经广泛研究了其在胃肠道,血管,肺和心脏生理调节中的作用,但在中枢神经系统(CNS)中的功能作用却很少受到关注。然而,当考虑文献中有关中央5-HT 2B R对多巴胺(DA)和5-羟色胺(5-HT)神经元活性施加的调控作用的可用数据时,出现了非常有趣的图片,并突出了关键作用这些受体用于DA相关神经精神疾病的未来治疗策略。

因此,本综述通过汇总过去二十年文献中的分子,生物化学,电生理和行为研究结果,旨在对目前的知识进行合理的分析,以支持中心5-HT 2B R对未来治疗途径的兴趣。。首先,我们回顾支持中枢神经系统5-HT / DA相互作用的治疗相关性的神经解剖学和功能性数据。此后,中央表达和5-HT的分子性质的简短概述之后2B R,以及的5-HT 2B在市场上可以买到R激动剂和拮抗剂,我们将重点研究这种受体在啮齿动物大脑中控制5-HT,DA和神经胶质细胞活性的功能。最后,将讨论5-HT 2B R拮抗剂对改善精神分裂症和药物成瘾的治疗潜力。

更新日期:2017-07-27
down
wechat
bug